Project Grant R21NS137066

Award Date 12/1/24
Completion Date 11/30/26
Dollars Obligated $247K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $560,934 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on neural coding and control of pain detection in the somatosensory cortex. The 5-year research project, which commenced on April 1, 2025, aims to: Define...
This Project Grant award of $158,512 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of Pittsburgh to characterize the role of orexinergic neurons in the spinal cord and their potential for treating chronic pain. The key research objectives are to: 1) use two-photon calcium imaging to investigate how orexin peptides impact the...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders provides $499,979 to The Salk Institute for Biological Studies to conduct research on the role of astrocytes in neuropathic pain. The key objectives are to: 1) determine how peripheral nerve injury alters dorsal horn astrocyte function, 2) elucidate how targeted interventions control dorsal horn...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify a circuit basis for neuropathic pain in the parabrachial nucleus. The $124,713 award, effective from December 1, 2024 to November 30, 2026, will be performed by the Beth Israel Deaconess Medical Center, Inc. in Boston, MA. The research aims to...
This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,750 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to research the role of the mesocortical glutamatergic pathway in the development and maintenance of chronic neuropathic pain. The project aims to use in vivo imaging, chemogenetics, and CRISPR/Cas9 gene editing to examine how alterations in ventral tegmental area (VTA) glutamatergic inputs to the prefrontal cortex contribute to chronic pain after peripheral nerve injury. It will also investigate whether activating this VTA-to-prefrontal cortex glutamatergic pathway can reverse established neuropathic pain independently of dopamine co-release. The research is expected to provide novel insights into targeting this pathway as a potential therapeutic strategy for chronic pain treatment. The award period is from Dec 1, 2024 to Nov 30, 2026.

Generated 8/5/25, 5:19 AM